204 related articles for article (PubMed ID: 32131709)
1. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
[No Abstract] [Full Text] [Related]
2. Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy.
Sabra MM; Sherman E; Tuttle RM
Clin Endocrinol (Oxf); 2019 Apr; 90(4):617-622. PubMed ID: 30706513
[TBL] [Abstract][Full Text] [Related]
3. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.
Sabra MM; Sherman EJ; Tuttle RM
Cancer; 2017 Aug; 123(15):2955-2964. PubMed ID: 28369717
[TBL] [Abstract][Full Text] [Related]
4. [Progression of diagnosis and treatment of medullary thyroid carcinoma].
Wang X; Li C; Huang L; Shui CY; Liu W; Cai YC; Sun RH; Zhou YQ; Jiang J; Wang W; Zeng DF
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Apr; 54(4):306-310. PubMed ID: 30991785
[No Abstract] [Full Text] [Related]
5. Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma.
Nigam A; Xu B; Spanheimer PM; Ganly I; Tuttle RM; Wong RJ; Shaha AR; Ghossein RA; Untch BR
Thyroid; 2022 Oct; 32(10):1193-1200. PubMed ID: 35950622
[No Abstract] [Full Text] [Related]
6. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
7. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
8. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
[TBL] [Abstract][Full Text] [Related]
9. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
11. PROGNOSTIC VARIABLES AFFECTING PRIMARY TREATMENT OUTCOME FOR MEDULLARY THYROID CANCER.
Momin S; Chute D; Burkey B; Scharpf J
Endocr Pract; 2017 Sep; 23(9):1053-1058. PubMed ID: 28683235
[TBL] [Abstract][Full Text] [Related]
12. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
13. Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Song E; Ahn J; Jeon MJ; Lee SM; Lee JH; Kim TY; Baek JH; Kim WB; Shong YK; Kim WG
Thyroid; 2020 Mar; 30(3):418-424. PubMed ID: 31880976
[No Abstract] [Full Text] [Related]
14. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
15. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
16. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
[TBL] [Abstract][Full Text] [Related]
17. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
18. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.
Ito Y; Miyauchi A; Kihara M; Kudo T; Miya A
Endocr J; 2016 Jul; 63(7):663-7. PubMed ID: 27097545
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study.
Twito O; Grozinsky-Glasberg S; Levy S; Bachar G; Gross DJ; Benbassat C; Rozental A; Hirsch D
Eur J Endocrinol; 2019 Jul; 181(1):13-21. PubMed ID: 31048559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
